Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	197.05	200.45	193.02	164.04	127.95	92.84
Revenue Growth (YoY)	-1.86%	3.85%	17.67%	28.20%	37.82%	60.39%
Cost of Revenue	88.8	89.35	83.59	63.06	48.81	41.13
Gross Profit	108.25	111.11	109.43	100.97	79.14	51.71
Selling, General & Admin	96.28	94.83	93.12	67.92	45.55	24.36
Research & Development	39.33	39.4	44.15	34.86	24.44	13.69
Operating Expenses	135.61	134.23	137.27	102.78	69.99	38.05
Operating Income	-27.36	-23.12	-27.85	-1.8	9.16	13.66
Interest Expense	-	-	-2.07	-2.57	-1.74	-0.33
Interest & Investment Income	9.66	10.36	6.41	4.62	0.05	0.11
Earnings From Equity Investments	-	-	-	0.04	0.04	-
Currency Exchange Gain (Loss)	-	-	-	-	-1.57	0.99
Other Non Operating Income (Expenses)	7.13	4.46	7.79	0.98	-	-
EBT Excluding Unusual Items	-10.57	-8.3	-15.71	1.26	5.94	14.43
Other Unusual Items	2.6	2.6	-	-	-	-
Pretax Income	-7.97	-5.7	-15.71	1.26	5.94	14.43
Income Tax Expense	3.28	0.32	-3.56	-1.22	2.91	-4.98
Earnings From Continuing Operations	-11.25	-6.02	-12.15	2.48	3.03	19.41
Minority Interest in Earnings	-	-	-	0.09	0.03	-
Net Income	-11.25	-6.02	-12.15	2.58	3.05	19.41
Preferred Dividends & Other Adjustments	-	-	-	-	3	16.2
Net Income to Common	-11.25	-6.02	-12.15	2.58	0.05	3.22
Net Income Growth	-	-	-	-15.62%	-84.27%	-
Shares Outstanding (Basic)	130	131	135	135	77	29
Shares Outstanding (Diluted)	130	131	135	139	82	33
Shares Change (YoY)	-3.11%	-3.45%	-2.37%	69.93%	150.13%	16.71%
EPS (Basic)	-0.09	-0.05	-0.09	0.02	0.00	0.11
EPS (Diluted)	-0.09	-0.05	-0.09	0.02	0.00	0.10
EPS Growth	-	-	-	2906.28%	-99.36%	-
Free Cash Flow	17.49	21.85	0.63	-21.98	0.27	13.61
Free Cash Flow Per Share	0.14	0.17	0.01	-0.16	0.00	0.42
Gross Margin	54.94%	55.43%	56.69%	61.56%	61.86%	55.70%
Operating Margin	-13.89%	-11.54%	-14.43%	-1.10%	7.16%	14.71%
Profit Margin	-5.71%	-3.00%	-6.29%	1.57%	0.04%	3.46%
Free Cash Flow Margin	8.88%	10.90%	0.33%	-13.40%	0.21%	14.66%
EBITDA	-19.98	-15.91	-21.8	0.69	10.4	14.26
EBITDA Margin	-10.14%	-7.94%	-11.29%	0.42%	8.13%	15.36%
D&A For EBITDA	7.39	7.21	6.05	2.49	1.24	0.6
EBIT	-27.36	-23.12	-27.85	-1.8	9.16	13.66
EBIT Margin	-13.89%	-11.54%	-14.43%	-1.10%	7.16%	14.71%
Effective Tax Rate	-	-	-	-	49.02%	-
Revenue as Reported	197.05	200.45	193.02	164.04	127.95	92.84

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q